Aisha Din-Shamas

Toronto, ON M5G2C1, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Allosteric Regulation of BH3 Proteins in Bcl-xL Complexes Enables Switch-like Activation of Bax.

Allosteric Regulation of BH3 Proteins in Bcl-xL Complexes Enables Switch-like Activation of Bax.

Journal: Molecular cell
Published: August 27, 2018

Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML.

Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML.

Journal: Blood
Published: October 03, 2016

Characterizing the mitochondrial DNA polymerase gamma interactome by BioID identifies Ruvbl2 localizes to the mitochondria.

Characterizing the mitochondrial DNA polymerase gamma interactome by BioID identifies Ruvbl2 localizes to the mitochondria.

Journal: Mitochondrion
Published: August 23, 2016

A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia.

A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia.

Journal: Cancer medicine
Published: June 01, 2016

A phase I study of elesclomol sodium in patients with acute myeloid leukemia.

A phase I study of elesclomol sodium in patients with acute myeloid leukemia.

Journal: Leukemia & lymphoma
Published: January 07, 2016

A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia.

A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia.

Journal: Oncotarget
Published: October 19, 2015

Increased pressure alters plasma membrane dynamics and renders acute myeloid leukemia cells resistant to daunorubicin.

Increased pressure alters plasma membrane dynamics and renders acute myeloid leukemia cells resistant to daunorubicin.

Journal: Haematologica
Published: July 18, 2015

FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.

FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.

Journal: Cell death & disease
Published: March 06, 2015

Distinct lipid effects on tBid and Bim activation of membrane permeabilization by pro-apoptotic Bax.

Distinct lipid effects on tBid and Bim activation of membrane permeabilization by pro-apoptotic Bax.

Journal: The Biochemical journal
Published: February 26, 2015

Drug discovery in academia.

Drug discovery in academia.

Journal: Experimental hematology
Published: January 31, 2015

Multiple partners can kiss-and-run: Bax transfers between multiple membranes and permeabilizes those primed by tBid.

Multiple partners can kiss-and-run: Bax transfers between multiple membranes and permeabilizes those primed by tBid.

Journal: Cell death & disease
Published: February 27, 2014

The proapoptotic protein tBid forms both superficially bound and membrane-inserted oligomers.

The proapoptotic protein tBid forms both superficially bound and membrane-inserted oligomers.

Journal: Biophysical journal
Published: September 25, 2013
Showing 1-12 of 15

Last Updated: 09/26/2026